Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: A randomized, double-blind pilot study

Molecular Medicine

Volumn 18, Issue 11, 2012, Pages 1430-1436

  Heij, Lara ^a   Niesters, Marieke ^a   Swartjes, Maarten ^a   Hoitsma, Elske ^b   Drent, Marjolein ^c,d   Dunne, Ann ^e   Grutters, Jan C ^f,g   Vogels, Oscar ^f   Brines, Michael ^e   Cerami, Anthony ^a,e   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Diaconessenhuis ^*  (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d GELDERSE VALLEI HOSPITAL   (Netherlands)

^e ARAIM PHARMACEUTICALS   (United States)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ARA 290; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLURRED VISION; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; FEMALE; FUNCTIONAL STATUS; HUMAN; MALE; MUSCLE CRAMP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS; SHORT FORM 36; SMALL FIBER NEUROPATHY; THORAX PAIN;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PEPTIDES; PILOT PROJECTS; PLACEBOS; QUESTIONNAIRES; SARCOIDOSIS; SENSATION; TREATMENT OUTCOME;

EID: 84872236234     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00332     Document Type: Article

References (28)

1. Chai J, Herrmann DN, Stanton M, Barbano RL, Logigian EL. (2005) Painful small-fiber neuropathy in Sjogren syndrome. Neurology. 65:925-7.
2. Tavee J, Culver D. (2011) Sarcoidosis and smallfiber neuropathy. Curr. Pain Headache Rep. 15:201-6.
3. Burns TM, Dyck PJ, Aksamit AJ. (2006) The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases. J. Neurol. Sci. 244:77-87.
4. Hoitsma E, De Vries J, Drent M. (2011) The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis. Respir. Med. 105:95-100.
5. Lower EE, Weiss KL. (2008) Neurosarcoidosis. Clin. Chest Med. 29:475-92, ix.
6. Bakkers M, et al. (2009) Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology. 73:1142-8.
7. Hoitsma E, et al. (2002) Small fibre neuropathy in sarcoidosis. Lancet. 359:2085-6.
8. Uceyler N, et al. (2010) Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology. 74:1806-13.
9. Brines M, et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 101:14907-12.
10. Bianchi R, et al. (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. U. S. A. 101:823-8.
11. Niesters M, et al. (2013) The erythropoietinanalogue ARA 290 for treatment of sarcoidosisinduced chronic neuropathic pain. Exp. Opin. Orphan Drugs. 1:77-87.
12. Swartjes M, et al. (2011) ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and betacommon receptor knockout mice. Anesthesiology. 115:1084-92.
13. Costabel U, Hunninghake GW. (1999) ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur. Respir. J. 14:735-7.
14. Rolke R, et al. (2006) Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur. J. Pain 10:77-88.
15. Magerl W, et al. (2010) Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain. 151:598-605.
16. De Vries J, Michielsen H, Van Heck GL, Drent M. (2004) Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br. J. Health Psychol. 9:279-91.
17. Farrar JT, Dworkin RH, Max MB. (2006) Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J. Pain Symptom Manage. 31:369-77.
18. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. (2012) Adalimumab successful in sarcoidosis patients with refractory chronic noninfectious uveitis. Graefes. Arch. Clin. Exp. Ophthalmol. 250:713-20.
19. Loza MJ, et al. (2011) Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin. Vaccine Immunol. 18:931-9.
20. Hoitsma E, et al. (2006) Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc. Diffuse Lung Dis. 23:73-7.
21. Elfferich MD, et al. (2010) Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration. 80:212-9.
22. Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA. (2011) Efficacy of intravenous immuno-globulin for small fiber neuropathy associated with sarcoidosis. Respir. Med. 105:101-5.
23. Wakasugi D, et al. (2009) Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjogren's syndrome. Mod. Rheumatol. 19:437-40.
24. Tavee J, Zhou L. (2009) Small fiber neuropathy: a burning problem. Cleve. Clin. J. Med. 76:297-305.
25. Brines M, Cerami A. (2008) Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J. Intern. Med. 264:405-32.
26. Brines M, Cerami A. (2012) The receptor that tames the innate immune response. Mol. Med. 18:486-96.
27. Schmidt RE, et al. (2011) Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp. Neurol. 232:126-35.
28. Gibbons CH, Wang N, Freeman R. (2010) Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann. Neurol. 68:888-98.